4D MOLECULAR THERAPEUTICS IN (FDMT) Stock Balance Sheet
NASDAQ:FDMT - Nasdaq - US35104E1001 - Common Stock - Currency: USD
| MRQ (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 133.53M | 149.34M | 249.11M | 52.40M | 153.00M | |||
| Marketable Securities | 187.91M | 275.54M | 39.12M | 161.20M | 94.80M | |||
| Receivables | N/A | N/A | N/A | 0.00 | 0.00 | |||
| Other Current Assets | 11.13M | 10.05M | 8.36M | 7.00M | 8.50M | |||
| Total Current Assets | 332.57M | 434.93M | 296.59M | 220.50M | 256.30M | |||
| Non-Current Assets | ||||||||
| PPE Net | 39.12M | 40.61M | 31.66M | 35.30M | 29.00M | |||
| Investments And Advances | 137.00M | 80.58M | 10.95M | 4.90M | 67.70M | |||
| Other Non-Current Assets | 7.04M | 4.26M | 684.00K | 1.10M | 600.00K | |||
| Total Non-Current Assets | 183.16M | 125.45M | 43.30M | 41.30M | 97.20M | |||
| TOTAL ASSETS | 515.73M | 560.38M | 339.89M | 261.80M | 353.50M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Accrued Expenses | 19.13M | 21.83M | 13.58M | 10.10M | 7.40M | |||
| Accounts Payable | 4.15M | 4.39M | 3.52M | 3.30M | 4.80M | |||
| Other Current Liabilities | 3.62M | 2.93M | 1.85M | 2.30M | 4.20M | |||
| Total Current Liabilities | 26.90M | 29.15M | 18.95M | 15.70M | 16.30M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Other Non-Current Liabilities | 19.11M | 20.63M | 13.11M | 14.80M | 18.00M | |||
| Total Non-Current Liabilities | 19.11M | 20.63M | 13.11M | 14.80M | 18.10M | |||
| TOTAL LIABILITIES | 46.01M | 49.78M | 32.06M | 30.50M | 34.40M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -624.17M | -576.20M | -415.33M | -314.50M | -207.00M | |||
| Additional Paid In Capital | 1.09B | 1.09B | 723.14M | 547.00M | 526.50M | |||
| Common Shares | 5.00K | 5.00K | 4.00K | 0.00 | 0.00 | |||
| Other Shareholders' Equity | 332.00K | 229.00K | 16.00K | -1.20M | -400.00K | |||
| Shares Outstanding | 46.32M | 45.79M | 43.08M | 32.60M | 32.20M | |||
| Tangible Book Value per Share | 10.14 | 11.15 | 7.15 | 7.10 | 9.91 | |||
| Total Shareholders' Equity | 469.72M | 510.61M | 307.83M | 231.30M | 319.10M | |||
| TOTAL LIABILITIES AND EQUITY | 515.73M | 560.38M | 339.89M | 261.80M | 353.50M | |||
| Statistics | ||||||||
| Current Ratio | 12.36 | 14.92 | 15.65 | 14.04 | 15.72 | |||
| Return On Assets (ROA) | -34.21% | -28.71% | -29.67% | -41.06% | -20.18% | |||
| Return On Equity (ROE) | -37.56% | -31.51% | -32.76% | -46.47% | -22.35% | |||
All data in USD , ROIC based on taxRate of 0.21